

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in



PRODUCT INFORMATION



Eliglustat-d₁₅ (tartrate) *Item No.* 30167

Formal Name: N-[(1R,2R)-2-(2,3-dihydro-1,4-

> benzodioxin-6-yl)-2-hydroxy-1-(1pyrrolidinylmethyl)ethyl]-octanamide-2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-d15, (2R,3R)-

2,3-dihydroxybutanedioate $C_{23}H_{21}D_{15}N_2O_4 \bullet C_4H_6O_6$

FW. 569.7

Chemical Purity: ≥98% (Eliglustat)


Deuterium

MF:

Incorporation: \geq 99% deuterated forms (d₁-d₁₅); \leq 1% d₀

Supplied as: A solid Storage: -20°C Stability: ≥2 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.



Laboratory Procedures

Eliglustat- d_{15} is intended for use as an internal standard for the quantification of eliglustat (Item No. 21487) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated versus unlabeled).

Eliglustat- d_{15} is supplied as a solid. A stock solution may be made by dissolving the eliglustat- d_{15} in the solvent of choice, which should be purged with an inert gas. Eliglustat- d_{15} is soluble in methanol and DMSO.

Description

Eliglustat is an inhibitor of glucosylceramide synthase (IC_{50} = 40 nM for inhibition of glucosylceramide production in K562 cells).¹ It is selective for glucosylceramide synthase over α-glucosidase I and II, α-1,6-glucosidase, lysosomal glucocerebrosidase, non-lysosomal glucosylceramidase, sucrase, and maltase (IC₅₀s = >10 μ M for all). It decreases cell surface levels of the gangliosides GM₁ and GM₃ in K562 and B16/F10 cells with IC₅₀ values of 24 and 29 nM, respectively. Eliglustat (150 mg/kg per day) decreases glucosylceramide levels in the liver and lungs of D409V/null mice, a model of Gaucher disease. Formulations containing eliglustat have been used in the treatment of type 1 Gaucher disease.

Reference

1. McEachern, K.A., Fung, J., Komarnitsky, S., et al. A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease. Mol. Genet. Metab. 91(3), 259-267 (2007).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

uyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 08/03/2020

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM